Bayer HealthCare Unveils Advances in CT Contrast Dose Management™ Solutions
Powerful New Certegra® Informatics Workstation launched at SIIM 2012
Intended for U.S. Media Only
TARRYTOWN, N.Y., June 7, 2012 /PRNewswire/ -- Bayer Radiology & Interventional announced the introduction of the Certegra® Workstation, an informatics-driven, touch‐screen hub that enables time savings and improved patient care through a powerful suite of CT Contrast Dose Management™ applications and a new P3T® 2.0 operating environment. The new Workstation will be presented at the annual meeting of the Society for Imaging Informatics in Medicine (SIIM) 2012 June 7 - 12 in Orlando, FL. Following the initial launch in the U.S. and Canada, the Workstation will be rolled out in phases in markets around the world.
The Workstation serves as a single interface for radiology technologists, enabling them to provide improved patient care from study set-up and preparation to administration of the patient's study. It will be the cornerstone of Bayer's industry-first Contrast Dose Management solution and informatics platform. In establishing and uploading the patient's contrast-injection record, the Workstation imports patient data directly from the Modality Work List – reducing manual entry errors to the patient record.
"Today's technology-driven CT suite demands timely access to reliable contrast-dose records throughout the chain of care," said Anthony Cinalli, vice president of the informatics business at Bayer Radiology & Interventional. "Enabling a single workflow-centralized interface, the Workstation allows for fewer clicks, less manual entry and greater control over the quality and consistency of patient care."
Interfacing with Medrad Stellant® CT injection systems, the Workstation's comprehensive suite of software options provides physicians and healthcare professionals instant access to real-time actionable CT contrast data captured at the point of care ̶ enabling benefits including:
- Reduce sub-diagnostic studies, unnecessary rescans and associated radiation exposure ,(P3T 2.0 for personalized CT abdominal, cardiac and pulmonary angiography studies)
- Enable more complete diagnostic decisions (PACS Outbound Interface)
- Speed-up radiology report turnaround time and create greater study-volume bandwidth (RIS and SR Outbound Interfaces)
- Improve department performance by trending, reporting and analyzing actionable data with pinpoint accuracy (Informatics Starter Package, and the Data Analysis and Reporting Tool)
Bayer HealthCare will have the Certegra® Workstation on display at its booth at SIIM 2012 (booth #217 - 221).
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
 Reference on file.
 Presented at Society of Thoracic Radiology (2008) Poster Session; Christopher R. Deible, MD, PhD. Study supported by MEDRAD Inc.
 510(k) FDA clearance number: K082905
SOURCE Bayer HealthCare
More by this Source
Bayer Receives Approval for Xofigo® (radium Ra 223 dichloride) Injection in Europe
Nov 15, 2013, 05:16 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.